Tag:

Medicinal Chemistry

Health

Calibr-Skaggs and Kainomyx join forces to accelerate development of antimalarial drugs

by Chief Editor
written by Chief Editor

Recent Alliance Targets Malaria’s Achilles’ Heel: The Parasite’s Skeleton

A groundbreaking research collaboration between the Calibr-Skaggs Institute for Innovative Medicines at Scripps Research and Kainomyx, Inc. Promises a fresh approach to combating malaria. Supported by the Gates Foundation, the partnership focuses on disrupting the Plasmodium parasite’s cytoskeleton – a strategy that could unlock a new generation of antimalarial drugs.

The Growing Threat of Drug Resistance

Malaria continues to be a global health crisis, with over 280 million cases and more than 600,000 deaths reported annually. The disease disproportionately impacts children and vulnerable populations in low- and middle-income countries. A major challenge is the increasing resistance of P. Falciparum, the deadliest malaria parasite, to existing treatments. This necessitates the urgent development of medicines with entirely new mechanisms of action.

Targeting the Cytoskeleton: A Novel Approach

Traditionally, antimalarial drug development has focused on metabolic pathways within the parasite. This new collaboration shifts the focus to the parasite’s cytoskeleton – the internal scaffolding that provides structure and enables movement. By disrupting this system, researchers aim to cripple the parasite’s ability to infect and replicate.

“We need to stay ahead of resistance by identifying and advancing compounds with entirely new mechanisms,” explains Case McNamara, senior director of infectious disease at Calibr-Skaggs. “Our collaboration with Kainomyx is designed to do just that: by targeting the parasite’s cytoskeleton, we open up a new front in the battle against this disease.”

Combining Expertise for Accelerated Discovery

The synergy between Calibr-Skaggs and Kainomyx is central to this initiative. Calibr-Skaggs brings its established drug discovery platform and a track record of advancing over a dozen drug candidates into clinical trials. Kainomyx contributes specialized expertise in cytoskeletal proteins, including their identification, purification, and structural analysis.

Kainomyx co-founder James Spudich, who as well co-founded Cytokinetics and MyoKardia, emphasizes the company’s commitment to translating fundamental biological insights into therapies. “Working with Calibr-Skaggs and with support from the Gates Foundation, we have an unprecedented opportunity to bring new hope to millions at risk of malaria,” he stated.

A Collaborative Pipeline

The collaboration will see Kainomyx providing key materials and conducting structural studies, although Calibr-Skaggs will lead medicinal chemistry efforts and high-throughput screening. Both organizations will jointly advance promising compounds through the drug discovery pipeline, with a commitment to open publication and global access.

“Our mission at Kainomyx is to harness the power of cytoskeletal science to address urgent global health challenges,” Spudich added.

Calibr-Skaggs’ Nonprofit Model and Commitment

Calibr-Skaggs’ unique nonprofit model allows it to prioritize global health needs over profit, fostering a collaborative environment for innovation. “Our mission is to translate scientific breakthroughs into real-world solutions for those most in need. Collaborations like this are essential to succeed in the global effort to eradicate malaria,” says Anil Gupta, director of medicinal chemistry at Calibr-Skaggs.

Frequently Asked Questions

What is the cytoskeleton? The cytoskeleton is a network of protein filaments within cells that provides structural support and enables movement.

Why is targeting the cytoskeleton a novel approach? Most current antimalarial drugs target the parasite’s metabolic processes. Targeting the cytoskeleton represents a new mechanism of action, potentially overcoming drug resistance.

What role does the Gates Foundation play? The Gates Foundation provides financial support for the research collaboration, recognizing the urgent need for new antimalarial therapies.

Will these drugs be accessible globally? Both organizations have committed to open publication and global access to any drugs developed through this collaboration.

What is Calibr-Skaggs’ track record? Calibr-Skaggs has advanced over a dozen drug candidates into clinical trials, including promising antimalarial agents.

0 comments
0 FacebookTwitterPinterestEmail
Health

Thermodynamic insights into histamine H1 receptor ligand binding

by Chief Editor
written by Chief Editor

The Future of Drug Design: Beyond Binding Affinity to Enthalpy and Entropy

For decades, drug discovery has largely focused on how tightly a molecule binds to its target. But a paradigm shift is underway, driven by a deeper understanding of the thermodynamic forces at play. Recent research, spearheaded by Professor Mitsunori Shiroishi at Tokyo University of Science, highlights the critical role of enthalpy and entropy – alongside binding affinity – in creating more effective and selective drugs. This isn’t just a subtle refinement; it’s a fundamental rethinking of how we approach pharmaceutical innovation.

GPCRs: The Prime Target for Thermodynamic Precision

G-protein-coupled receptors (GPCRs) are a massive family of cell surface proteins responsible for recognizing hormones, neurotransmitters, and, crucially, a significant portion of existing drugs – over 30%. The histamine H1 receptor (H1R), a key GPCR, is central to allergic reactions, inflammation, and even neurological functions like wakefulness. Current antihistamines, while helpful, often have limitations in efficacy, prompting scientists to explore new design strategies.

The Enthalpy-Entropy Compensation: A Delicate Balance

Traditionally, drug design prioritized maximizing binding energy. Though, researchers are now recognizing that the interplay between enthalpy (the heat released or absorbed during binding) and entropy (a measure of disorder or randomness) is equally important. This “enthalpy-entropy compensation” dictates how selectively a drug interacts with its target. Measuring these thermodynamic parameters has been historically challenging for complex proteins like GPCRs, but new techniques are changing that.

Unlocking H1R Secrets with Doxepin Isomers

Professor Shiroishi’s team focused on doxepin, a tricyclic antidepressant that also acts as an antihistamine by targeting H1R. Doxepin exists as two geometric isomers – E– and Z-isomers – with the Z-isomer exhibiting a significantly higher affinity for H1R. The team’s investigation, published in ACS Medicinal Chemistry Letters, revealed that this difference isn’t just about how strongly each isomer binds, but how they bind.

Using a combination of isothermal titration calorimetry and molecular dynamics simulations, they discovered that binding to the wild-type H1R was primarily driven by enthalpy, while a mutated receptor showed a greater reliance on entropy. The Z-isomer demonstrated a larger enthalpic gain and a greater entropic penalty compared to the E-isomer, a difference lost in the mutated receptor. This highlights the crucial role of a specific threonine residue (Thr1123.37) in orchestrating this thermodynamic balance.

Conformational Constraints: The Key to Selectivity

Molecular dynamics simulations further revealed that the high affinity of the Z-isomer stems from conformational restrictions – it essentially locks into a favorable shape upon binding. This rigidity contributes to the enthalpic gain but reduces entropy. Understanding these conformational dynamics is proving vital for designing drugs that selectively target specific receptors.

Implications for Future Drug Development

This research has far-reaching implications. It suggests that future drug design will move beyond simply maximizing binding affinity to carefully engineering the enthalpy and entropy of ligand-receptor interactions. This could lead to:

  • Improved Selectivity: Drugs that target only the intended receptor, minimizing off-target effects and side effects.
  • Enhanced Efficacy: More potent drugs that require lower doses for the same therapeutic effect.
  • Longer-Lasting Effects: Drugs with optimized thermodynamic properties may exhibit prolonged activity within the body.

Beyond H1R: A Universal Principle

The principles uncovered in this study aren’t limited to the histamine H1 receptor. The enthalpy-entropy trade-off is likely a fundamental aspect of how all proteins interact with ligands. The research team believes their approach – combining thermodynamic analysis with molecular dynamics simulations – can be applied to a wide range of GPCRs and other proteins, accelerating the development of new therapeutics across various disease areas.

FAQ

Q: What are enthalpy and entropy?
A: Enthalpy relates to the energy released or absorbed during a chemical interaction, while entropy measures the degree of disorder or randomness. Both play a crucial role in determining how a drug binds to its target.

Q: Why is understanding GPCRs important?
A: GPCRs are involved in a vast number of physiological processes and are the target of over 30% of currently marketed drugs.

Q: What are drug isomers?
A: Isomers are molecules with the same chemical formula but different arrangements of atoms. These subtle differences can significantly impact their biological activity.

Pro Tip

Keep an eye on advancements in computational chemistry and molecular dynamics simulations. These tools are becoming increasingly powerful for predicting and optimizing the thermodynamic properties of drug candidates.

Want to learn more about the latest breakthroughs in pharmaceutical research? Subscribe to our newsletter for regular updates and insights.

0 comments
0 FacebookTwitterPinterestEmail
Health

Lower hinge of immunoglobulin G acts as a critical immune control hub

by Chief Editor
written by Chief Editor

The Hidden Key to Antibody Power: How a Tiny Region Could Revolutionize Disease Treatment

For decades, scientists have focused on the arms and stem of antibodies – the parts that grab onto invaders and signal the immune system. But a groundbreaking study from the Institute of Science Tokyo reveals a surprising truth: the lower hinge, a small, often-overlooked segment connecting these parts, is a critical “structural and functional control hub.” This discovery isn’t just academic; it’s poised to reshape the future of antibody-based therapies for diseases ranging from cancer to autoimmune disorders.

Understanding the Antibody Architecture: Beyond the Arms and Stem

Antibodies, the Y-shaped proteins that defend our bodies, are remarkably complex. The two “arms” (Fab regions) identify and bind to specific targets – viruses, bacteria, or even cancer cells. The “stem” (Fc region) then alerts the immune system to launch an attack. The hinge region, acting as a flexible connector, allows these parts to move and interact effectively. Think of it like the joint in your arm – without it, movement and function would be severely limited.

IgG, the most abundant antibody in our blood, comprises roughly 75% of the total antibody population. Its hinge isn’t a uniform structure. It’s a “mosaic” with a rigid core flanked by more flexible upper and lower segments. Until now, research largely bypassed the lower hinge, assuming its role was minimal. This assumption has now been challenged.

The Proline Puzzle: A Single Amino Acid Makes All the Difference

Researchers, led by Associate Professor Saeko Yanaka, systematically investigated the impact of altering the lower hinge region of trastuzumab, a widely used antibody in breast cancer treatment. Their key finding? Removing a single amino acid, proline (Pro230), dramatically altered the antibody’s structure and function. This deletion resulted in a “half-IgG1” molecule – a stable but incomplete antibody.

This half-antibody exhibited a disrupted disulfide bonding pattern, meaning the two halves of the antibody weren’t securely linked. Imaging revealed a crucial shift in the orientation of the Fab and Fc regions. Normally, the Fc region pairs up to interact with immune receptors. In the half-antibody, this pairing surface rotated inward, hindering the normal immune signaling process. Despite this disruption, the half-antibody still retained some ability to bind to immune cells, albeit less effectively.

Did you know? The human body produces millions of different antibodies, each designed to recognize a specific threat. The ability to fine-tune antibody function through hinge region engineering could unlock a new era of personalized medicine.

Engineering Antibodies for Precision Medicine: The Future is Now

The implications of this research are far-reaching. By understanding how the lower hinge controls antibody shape, stability, and function, scientists can now engineer antibodies with precisely tailored immune effects. This opens doors to:

  • Enhanced Cancer Therapies: Designing antibodies that more effectively recruit immune cells to destroy cancer cells, or conversely, reducing unwanted immune responses that can cause side effects.
  • Targeted Autoimmune Treatments: Creating antibodies that selectively suppress the immune response in autoimmune diseases, minimizing damage to healthy tissues. For example, in rheumatoid arthritis, antibodies could be engineered to block specific inflammatory pathways without broadly suppressing the immune system.
  • Improved Vaccine Development: Optimizing antibody responses to vaccines, leading to stronger and longer-lasting immunity.
  • Novel Drug Delivery Systems: Utilizing modified antibodies to deliver drugs directly to diseased cells, maximizing efficacy and minimizing off-target effects.

Recent advancements in computational biology and protein engineering are accelerating this process. AI-powered algorithms can now predict the impact of specific hinge region modifications, streamlining the design and testing of new antibody variants. Companies like Regeneron and Amgen are already heavily invested in antibody engineering, and this new research will undoubtedly influence their future strategies.

Beyond IgG1: Expanding the Scope of Hinge Region Research

While this study focused on IgG1 antibodies, the principles likely extend to other IgG subclasses and even other antibody types like IgA and IgM. Further research is needed to explore the hinge region’s role in these different antibody structures. Understanding these nuances will be crucial for developing a truly comprehensive understanding of antibody function.

Pro Tip: Keep an eye on publications in journals like Nature Immunology, Science Immunology, and the Journal of Medicinal Chemistry for the latest breakthroughs in antibody engineering.

FAQ: Your Questions Answered

  • What is the hinge region of an antibody? It’s the flexible segment connecting the antibody’s arms (Fab regions) to its stem (Fc region), crucial for movement and function.
  • Why is the lower hinge important? It acts as a “structural and functional control hub,” influencing antibody shape, stability, and immune signaling.
  • How could this research impact cancer treatment? It could lead to antibodies that more effectively target and destroy cancer cells, with fewer side effects.
  • Will this lead to new drugs immediately? While promising, further research and clinical trials are needed before new therapies become available.

This discovery marks a significant turning point in antibody research. By unlocking the secrets of the lower hinge, scientists are paving the way for a new generation of antibody therapies that are more precise, more effective, and ultimately, more beneficial to patients worldwide.

Want to learn more? Explore our articles on immunotherapy and antibody therapeutics to delve deeper into the world of immune-based treatments.

0 comments
0 FacebookTwitterPinterestEmail